Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03455582
Other study ID # CHUBX 2017/14
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 24, 2018
Est. completion date March 2026

Study information

Verified date March 2023
Source University Hospital, Bordeaux
Contact Aurélie RUET, Prof
Phone 05 56 79 55 21
Email aurelie.ruet@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%. Cognitive impairment affects quality of life and vocational status in MS patients. Until recently, little information was available on the cognitive dysfunction and their evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation suggesting that the GM alteration could play a major role in the cognitive impairment in this phenotype. The cognitive evolution and the brain tissue alteration at the origin of these difficulties remain poorly understood in PPMS. The use of new techniques for morphological and functional MRI can study the contribution of diffuse White Matter (WM) alteration (probably through disconnexion of relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS patients and on their evolution.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date March 2026
Est. primary completion date March 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: PATIENTS - Male or female; - Age = 18 years; - PPMS diagnosis according to McDonald 2010 criteria; - Disease duration = 15 years; - Native French speaking; - Being affiliated to health insurance; - Willing to participate and to sign informed consent. HEALTHY CONTROLS - Male or Female; - Age = 18 years; - Native French speaking; - Being affiliated to health insurance; - Willing to participate and to sign informed consent. Exclusion Criteria: PATIENTS - previous history of other neurological disease; - psychiatric comorbidity including severe depression according to DSM-IV; - alcohol or other addiction to toxic; - disabling visual or motor problems preventing participation to neuropsychological assessments; - change of psychotropic drug since less than one month; - contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body,claustrophobia or refusing MRI); - illiteracy, is unable to count or to read; - pregnant or breastfeeding women; - patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent). HEALTHY CONTROLS - history of neurological disease; - family history of MS; - psychiatric comorbidity including severe depression according to DSM-IV; - alcohol or other toxic addiction; - psychotropic drugs; known cognitive complaint or neuropsychological affection; - prior neuropsychological testing with the same tests less than 6 months - contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, meta fragments or foreign objects in the eyes, skin or body, claustrophobia or refusing MRI); - illiteracy, is unable to count or to read; - pregnant or breastfeeding women; - person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Clinical assessment
Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
Ecological evaluation
Virtual reality task and Actual reality
Neuropsychological evaluation
cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Psychological evaluation
questionnaires for depression, anxiety and fatigue
Device:
MRI Evaluation
morphological MRI and resting state functional MRI (fMRI)

Locations

Country Name City State
France CHU de Bordeaux Bordeaux
France CHU de Limoges Limoges
France CHU de Poitiers Poitiers

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux Roche Pharma AG

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of composite z cognitive score based on individual neuropsychological scores The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time (baseline and 2 years).
Individual neuropsychological scores included in composite z cognitive score : the Alertness subtest, the divided attention subtest and the visual-scanning subtest from the TAP, The Symbol-digit-modalities-test, the Paced-Auditory-Serial-Addition-Test 3s, reversed span, the Stroop test, the Verbal fluency, Trail Making test, the California Verbal memory learning test and the Brief visual memory test -revised
At baseline (day 0) and at 24 months from baseline
Secondary Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.
The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.
At baseline (day 0) and at 24 months from baseline
Secondary Change of composite z cognitive score based on individual neuropsychological scores The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. At baseline (day 0), at 12 months and at 24 months from baseline
Secondary Changes of composite z ecological score based on individual ecological scores The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests. At baseline (day 0), at 12 months and at 24 months from baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04544449 - A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Phase 3
Completed NCT06436131 - The Effects of In-phase Bilateral Exercise in People With Progressive Multiple Sclerosis N/A
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT02913157 - Hydroxychloroquine in Primary Progressive Multiple Sclerosis Phase 2
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Completed NCT01194570 - A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Phase 3
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Completed NCT03679468 - Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation N/A
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Temporarily not available NCT02606929 - Use of Well Known Drugs for New Destination - MS Improvement (MSNT) Phase 0
Completed NCT03424538 - The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients N/A
Completed NCT04545372 - Aerobic Exercises for Multiple Sclerosis N/A
Recruiting NCT05122559 - Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT02988401 - Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Phase 1/Phase 2
Completed NCT02632591 - Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment Phase 1
Completed NCT01917019 - A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Phase 3
Completed NCT01433497 - Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Phase 3